Southeast Asia (SEA) represents one of the world’s most underutilized regions for clinical research. Despite comprising nearly 8% of the global population and disease burden, it contributes less than 2% of total clinical trials — a striking imbalance that underscores both the unmet medical need and the untapped market potential. For global sponsors and Contract Research Organizations (CROs) seeking cost-effective, diverse patient access, this gap represents a compelling growth opportunity.
Within this landscape, Indonesia stands out as the region’s largest and most underleveraged player. Home to more than 275 million people — over 40% of SEA’s population — the country offers unparalleled scale for patient recruitment and disease diversity. Yet, for decades, its participation in global clinical trials has remained low, constrained by regulatory fragmentation, inconsistent quality standards and limited trial infrastructure. These barriers have historically disincentivized multinational engagement and kept Indonesia on the periphery of global R&D ecosystems.
This dynamic is changing rapidly. Through decisive structural reforms, the Indonesian Ministry of Health has taken bold steps to reposition the country as a credible and competitive destination for clinical research. Central to this transformation is the establishment of the Indonesian Clinical Research Consortium (INA-CRC), a new national body tasked with centralizing oversight, streamlining regulatory approvals and standardizing processes across institutions. These reforms are fostering a more transparent, efficient and predictable environment — one that reduces start-up times, enhances data reliability and aligns local practices with international standards.
As a result, Indonesia’s clinical trial landscape is entering an inflection point. The market is expected to expand significantly, with local trial volumes projected to triple to around 300 studies and reach a value of $1 billion to $1.5 billion in the medium term. Beyond the numbers, the broader opportunity lies in Indonesia’s evolution into a regional hub — anchored by its demographic scale, cost competitiveness and growing institutional capability.
For biopharma sponsors and CROs, now is the time to engage. With reform momentum building and investor confidence rising, Indonesia offers a rare first-mover advantage in a market poised for structural takeoff — transforming from an overlooked segment into a cornerstone of SEA’s clinical research future.
For further insights into our analysis, download the full presentation.
Contact us for more information.
L.E.K. Consulting is a registered trademark of L.E.K. Consulting LLC. All other products and brands mentioned in this document are properties of their respective owners. © 2025 L.E.K. Consulting LLC
11262025101141